Alpha Cog™
Treat & Prevent Cognitive Deficits across Brain Disorders & During Aging

Alpha Cog™ is a preclinical pharma spinoff founded by the Centre for Addiction and Mental Health (CAMH) and Dr. Etienne Sibille. The mission of Alpha Cog™ is to discover and develop small molecules for the treatment and prevention of cognitive symptoms in depression and other brain disorders.

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype 613 472 Thomas Prevot

The paper was published by Fee et al. in the International Journal of Neuropsychopharmacology. Patients suffering from mood and anxiety disorders often exhibit a deficit in brain inhibition. This deficit…

A new molecule shows efficacy at reversing brain atrophy observed during aging

A new molecule shows efficacy at reversing brain atrophy observed during aging 639 450 Thomas Prevot

Drs. Prevot, Sibille and Colleagues just published their finding in the Journal Cerebral Cortex, about a new molecule reversing brain atrophy and memory dysfunction observed during aging. During aging, our…

Alpha Cog graduates from the Creative Destructive Lab – Edition 2019-2020

Alpha Cog graduates from the Creative Destructive Lab – Edition 2019-2020 256 256 Thomas Prevot

Our team is proud of being part of the graduating ventures participating in the 2019-2020 Edition of the Creative Destruction Lab (CDL). CDL is a nonprofit organization that delivers an…

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders 1920 800 Etienne Sibille

Cognitive dysfunctions, including impaired attention, learning, memory, planning and problem solving, occur in depressive episodes, often persist during remission, predict relapse, worsen with recurrent episodes, and are not treated by current antidepressants or other medications.

CAMH Engage Breakthrough Challenge 2019 awarded to Dr. Thomas Prevot

CAMH Engage Breakthrough Challenge 2019 awarded to Dr. Thomas Prevot 1440 780 Etienne Sibille

On October the 18th, a sold-out crowd of nearly 300 young professionals gathered at Ricarda’s Toronto to award $10,000 as part of the 6th Annual Breakthrough Challenge, a signature event…

BBC World News

February 15, 2019

Dr. Etienne Sibille presented key findings on new compounds for cognitive dysfunction in depression and aging, live on BBC News, after the AAAS meeting in Washington D.C.